Quality of Life in the Phase 2/3 Trial of N-803 Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
Karim ChamieSam S ChangEugene V KramolowskyMark L GonzalgoMegan HuangPaul BharPatricia SpilmanLennie SenderSandeep K ReddyPatrick Soon-ShiongPublished in: Urology practice (2024)
The overall stability of PROs scores taken together with the efficacy findings, indicate a favorable risk/benefit ratio and quality of life following N-803 plus BCG.
Keyphrases